Skip to main content
Canna~Fangled Abstracts

Analyzing the Impact of Cannabinoids on the Treatment of Spinal Disorders

By February 8, 2022No Comments

Review
. 2022 Feb 8.

doi: 10.1007/s12178-022-09743-w.

Online ahead of print.
Rohan M Shah 1, Anjay Saklecha 1, Alpesh A Patel 2, Srikanth N Divi 3
Affiliations 

Abstract

Purpose of review: Cannabis is among the most used illicit substances globally, with medical applications, increased legalization, and shifting social attitudes leading to increased use in recent years. Cannabinoids are a group of psychoactive substances found within the cannabis plant, with the most common being Δ9-tetrahydrocannabinol and cannabidiol. Due to the high prevalence of use, it is increasingly important to evaluate the effects of cannabis and cannabinoids on spine patients, in both operative and nonoperative settings.

Recent findings: Cannabis and cannabinoids may be effective in treating patients with chronic conditions such as back pain and spinal cord injuries. Longitudinal effects and implications on surgical outcomes and complications are poorly understood. High-quality, outcomes-focused research can inform approaches for clinicians to approach cannabis and cannabinoid use. Studies to elucidate the standardization of cannabis regimens can help develop guidelines for potential therapeutic applications. Cannabis and cannabinoids may be useful alternatives or additions for many spine patients, but future research is needed for recommendations to be determined. Our manuscript reviews the available literature regarding cannabis use and various spinal conditions, organizing our findings into the following narrative themes: (1) the management of chronic lower back pain, (2) perioperative outcomes, (3) cannabis use in general orthopaedic procedures, and (4) spinal cord injuries.

Keywords: Cannabinoids, Cannabis, Spine, Spine outcomes

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Botsford SL, Yang S, George TP. Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential. Am J Addict. 2020;29(1):9–26. https://doi.org/10.1111/ajad.12963 . – DOI – PubMed
    1. Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P T. 2017;42(3):180–8. – PubMed – PMC
    1. Lafaye G, Karila L, Blecha L, Benyamina A. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017;19(3):309–16. https://doi.org/10.31887/DCNS.2017.19.3/glafaye . – DOI – PubMed – PMC
    1. Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci. 2020;411:116717. https://doi.org/10.1016/j.jns.2020.116717 . – DOI – PubMed
    1. Leos-Toro C, Shiplo S, Hammond D. Perceived support for medical cannabis use among approved medical cannabis users in Canada. Drug Alcohol Rev. 2018;37(5):627–36. https://doi.org/10.1111/dar.12823 . – DOI – PubMed

Publication types

Leave a Reply